Tasly Pharmaceutical Group Co., Ltd

600535

CNE000001C81

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
14.9 ^CNY	0.00%		-2.10%	-12.46%

Apr. 16	Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat	MT
Apr. 15	Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tasly Pharmaceutical Group Plans to Spin Off and List Its Biomedicine Unit

May 07, 2020 at 11:14 am EDT

Tasly Pharmaceutical Group Co. Ltd. (SHSE:600535) said it plans to spin off its biomedicine unit and list in Shanghai star market.

Latest news about Tasly Pharmaceutical Group Co., Ltd

Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat	Apr. 16	MT
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Shanghai Yuesai Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Tasly Pharmaceutical Group Co., Ltd, Shanghai Pudong Venture Investment Co., Ltd. and other investors	Apr. 02	CI
Tasly Pharmaceutical Gets Nod to Trial Stem Cell Therapy	Jan. 19	MT
ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units	Dec. 29	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) added to S&P Global BMI Index	23-09-18	CI
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) added to FTSE All-World Index	23-09-18	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Mauna Kea Technologies SA announced that it has received €2.3 million in funding from Tasly Pharmaceutical Group Co., Ltd	23-05-30	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Mauna Kea: soaring after quarterly sales figures	23-04-21	CF
Tasly Pharmaceutical Gets Go Ahead to Launch Clinical Trial of Diabetic Kidney Drug	22-12-19	MT
Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China	22-11-07	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Tasly Pharmaceutical Wins Nod For Clinical Trial of Psoriasis Drug	22-09-30	MT
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Tasly Pharmaceutical Group Scraps Plan to Spin Off BioPharm Unit for Listing	22-08-19	CI
Transcript : Mauna Kea Technologies SA, Tasly Pharmaceutical Group Co., Ltd - M&A Call	22-07-12
Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements	22-07-11	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on June 26, 2021.	22-01-04	CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on June 26, 2021.	21-10-11	CI

Chart Tasly Pharmaceutical Group Co., Ltd

Duration

Period

Chart Tasly Pharmaceutical Group Co., Ltd

More charts

Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Tasly Pharmaceutical Group Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

14.9 CNY

Average target price

12.73 CNY

Spread / Average Target

-14.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
TASLY PHARMACEUTICAL GROUP CO., LTD	-12.46%	3.06B
DONG-E-E-JIAO CO.,LTD.	+37.37%	6.05B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.69%	4.45B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.12%	3.04B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.47%	2.58B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+36.06%	1.79B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.84%	1.66B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-10.60%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.03%	1.54B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+36.40%	1.42B

Alternative Medicine

Tasly Pharmaceutical Group Co., Ltd

Equities

600535

CNE000001C81

Pharmaceuticals

Tasly Pharmaceutical Group Plans to Spin Off and List Its Biomedicine Unit

Latest news about Tasly Pharmaceutical Group Co., Ltd

Chart Tasly Pharmaceutical Group Co., Ltd

Company Profile

Income Statement Evolution

Ratings for Tasly Pharmaceutical Group Co., Ltd

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Alternative Medicine